Menopause is the permanent cessation of menstruation, defined retroactively after 12 consecutive months of amenorrhea. The average age of menopause is 51 (range 45-55). Premature menopause (before age 40) affects 1% of women.

Menopause illustration — Menopause is the permanent cessation of menstruation diagnosed after 12 months of amenorrhea. The average age of menopause is 51 years. Source: Unsplash.

The Menopausal Transition

Perimenopause

Perimenopause is the 2-8 year transition before menopause. Ovarian function declines, with decreased inhibin B and increased FSH levels. Estrogen levels become variable — periods of high estrogen (anovulatory cycles produce unopposed estrogen) followed by low estrogen. Cycle length becomes variable (shorter cycles initially, then longer with skipped periods). Perimenopause ends 12 months after the final menstrual period. Common perimenopausal symptoms: irregular periods, vasomotor symptoms (hot flashes, night sweats), sleep disturbance, mood changes, vaginal dryness and dyspareunia, breast tenderness, and heavier or lighter bleeding.

Postmenopause

Postmenopause begins 12 months after the last menstrual period and continues throughout the remainder of life. Estrogen levels are consistently low (estradiol under 20 pg/mL). Long-term health consequences of estrogen deficiency include accelerated bone loss (1-2% per year in the first 3-5 years, then 0.5-1% per year), increased cardiovascular risk, urogenital atrophy (vaginal dryness, dyspareunia, urinary frequency, urgency), and cognitive changes.

Common Symptoms

Breastfeeding — Common menopause symptoms include vasomotor symptoms, sleep disturbance, and vaginal dryness. Source: Unsplash.

Vasomotor Symptoms

Hot flashes and night sweats affect 60-80% of women during the menopausal transition. They are characterized by sudden sensation of intense heat, sweating, flushing, and sometimes palpitations and anxiety, lasting 1-5 minutes. The frequency and severity vary. Vasomotor symptoms last an average of 7 years (longer in African American and Hispanic women). The mechanism involves narrowing of the thermoneutral zone (narrower temperature regulation window due to estrogen withdrawal).

Sleep Disturbance

Sleep disruption in menopause is multifactorial: night sweats (common in perimenopause), mood changes, and age-related changes in sleep architecture. Sleep quality often improves with treatment of vasomotor symptoms.

Vaginal and Genitourinary Symptoms

Genitourinary syndrome of menopause includes vaginal dryness, dyspareunia, vaginal itching and irritation, urinary frequency, urgency, and recurrent UTIs. These symptoms tend to progress over time and do not resolve without treatment. Estrogen deficiency leads to thinning of vaginal epithelium, decreased lubrication, loss of vaginal elasticity, and increased vaginal pH (leading to changes in the microbiome).

Mood and Cognition

Perimenopause and early postmenopause are associated with an increased risk of depressive symptoms (especially in women with prior depression or PMS/PMDD). Cognitive complaints (“brain fog”) are common during perimenopause but objective testing often shows no significant decline — these symptoms improve after menopause.

⚠ Clinical Correlation

Menopausal hormone therapy (HT) is the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause. It also prevents bone loss. The decision to use HT requires individualized risk-benefit assessment. The Women’s Health Initiative (WHI) showed that combined estrogen-progestin therapy increases the risk of breast cancer (8 additional cases per 10,000 woman-years), stroke (8 per 10,000), VTE (18 per 10,000), and dementia (in women over 65), while reducing hip fractures (5 per 10,000) and colon cancer (6 per 10,000). Estrogen-only therapy (in women with hysterectomy) does not increase breast cancer risk and may reduce it, but still increases stroke and VTE risk. Current recommendations: use the lowest effective dose for the shortest duration, starting for women under 60 or within 10 years of menopause onset (the “window of opportunity” for cardiovascular benefit without increased coronary risk). HT is not recommended for primary prevention of chronic disease. Contraindications: breast cancer, endometrial cancer (estrogen-only in those with a uterus), undiagnosed vaginal bleeding, active liver disease, and history of VTE (oral therapy — transdermal estrogen has lower VTE risk). Types: systemic HT for vasomotor symptoms (oral or transdermal estrogen + progestin for those with a uterus), and local vaginal estrogen (creams, tablets, rings) for genitourinary symptoms with minimal systemic absorption.

Non-Hormonal Management of Vasomotor Symptoms

For women who cannot or prefer not to take HT, options include SSRIs/SNRIs (paroxetine 7.5-12.5 mg, venlafaxine 37.5-75 mg, escitalopram 10-20 mg), gabapentin (300-900 mg at bedtime), and pregabalin. Paroxetine is the only non-hormonal medication FDA-approved for vasomotor symptoms. Lifestyle measures: dressing in layers, avoiding triggers (hot drinks, spicy foods, alcohol, stress), maintaining a cool environment, and slow, deep breathing during hot flashes. Cognitive behavioral therapy and hypnosis have evidence of benefit.

Bone Health After Menopause

Estrogen deficiency accelerates bone loss. All postmenopausal women should consume 1,200 mg of calcium daily (diet plus supplements if needed) and 800-1,000 IU of vitamin D daily. Weight-bearing exercise (walking, jogging, resistance training) preserves bone density. DEXA scan for osteoporosis screening is recommended at age 65 (or earlier with risk factors). Pharmacologic treatment (bisphosphonates — alendronate, risedronate, zoledronic acid; denosumab; raloxifene; or HT) is indicated for osteoporosis (T-score under -2.5) or osteopenia with high fracture risk (FRAX 10-year hip fracture risk over 3% or major osteoporotic fracture risk over 20%).

Summary

Menopause is diagnosed after 12 months of amenorrhea (average age 51). Perimenopause involves variable estrogen levels and menstrual irregularity. Vasomotor symptoms (hot flashes, night sweats) affect 60-80% of women. Hormone therapy is the most effective treatment when initiated in women under 60 within 10 years of menopause onset — risks are low in this window. Non-hormonal options include SSRIs, gabapentin, and lifestyle measures. Bone health requires adequate calcium and vitamin D, weight-bearing exercise, and screening for osteoporosis.